argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
- Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up to $1.6 billion potentially
- Janssen to pay argenx $300 million in upfront cash payment
- Johnson & Johnson Innovation ? JJDC, Inc. (JJDC) to make $200 million equity investment in argenx
- argenx to retain right to co-promote cusatuzumab in the U.S. and share economics 50-50 on a royalty basis
- Conference call to be held today at 5:00 PM CET (11:00 AM ET/8:00 AM PT)
- International dial-in: +44 (0) 207 192 8000
- US: 16315107495 (or 18669661396)
- UK: 08445718892
- Belgium: 024009874
- The Netherlands: 0207143545
- France: 0176700794
- Sweden: 0850692180
- Switzerland: 0315800059